Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
10/12/2025 13:05
Dec 10 (Reuters) - Barinthus Biotherapeutics PLC 2ABy.F: BARINTHUS BIO ANNOUNCES UPDATE ON PHASE 1 AVALON CLINICAL TRIAL OF VTP-1000 FOR THE TREATMENT OF CELIAC DISEASE BARINTHUS BIOTHERAPEUTICS PLC - VTP-1000 WELL-TOLERATED WITH NO TREATMENT-RELATED SAES Source text: ID:nGNX7Rs1mp Further company coverage: [2ABy.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing